Evidence map›Paper›PMID 38133871›Full record

ReviewJournal of gastrointestinal cancer2024

Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma.

Katherine I Zhou, Brent A Hanks, John H Strickler

Open access · greenAbstract readReview
In one paragraph

Review in Journal of gastrointestinal cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Katherine I ZhouDivision of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA.ORCID http://orcid.org/0000-0001-6442-0475
Brent A HanksDivision of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA.ORCID http://orcid.org/0000-0002-2803-3272
John H StricklerDivision of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA. john.strickler@duke.edu.ORCID http://orcid.org/0000-0001-7579-1175
Duke University · USDuke Medical Center · US

Funding

TRANSFUSION MEDICINE AND RELATED AREAST32HL007057 · NHLBI · DUKE UNIVERSITY · PI Gowthami M Arepally · 1985 to 2026
$10.6M
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapyR37CA249085 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HANKS, BRENT ALLEN · 2020 to 2025
$2.5M
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicitiesR01CA251136 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brent Allen Hanks · 2021 to 2026
$1.9M
Duke University Duke Health Scholars AwardNational Cancer Institute, United States 5R01-CA251136NCI NIH HHS R01 CA251136NCI NIH HHS R37 CA249085NHLBI NIH HHS T32 HL007057U.S. Department of Defense W81XWH2110847
6 · The paper itself

Abstract

backgroundGastroesophageal cancer is a major cause of cancer-related mortality worldwide. Treatment of both early stage and advanced disease remains highly reliant on cytotoxic chemotherapy. About 4-24% of gastroesophageal cancers are microsatellite instability high (MSI-H). The MSI-H subtype is associated with favorable prognosis, resistance to cytotoxic chemotherapy, and sensitivity to immune checkpoint inhibitors (ICI). Recent studies have demonstrated promising activity of ICIs in the MSI-H subtype, resulting in fundamental changes in the management of MSI-H gastroesophageal adenocarcinoma. PURPOSE: In this review, we discuss the prevalence, characteristics, prognosis, and management of MSI-H gastroesophageal adenocarcinoma, with a focus on recent and ongoing studies that have changed the landscape of treatment for the MSI-H subtype. We also discuss current challenges in the management of resectable and advanced MSI-H gastroesophageal cancer, including the need for more accurate biomarkers of response to ICI therapy.

Indexed as

AdenocarcinomaEsophageal NeoplasmsMicrosatellite InstabilityStomach NeoplasmsBiomarkers, TumorEsophagogastric JunctionHumansImmune Checkpoint InhibitorsPrognosisBiomarkers, TumorImmune Checkpoint InhibitorsGastroesophageal adenocarcinomaImmunotherapyMicrosatellite instabilityMolecular biomarkers

Identifiers

PMID38133871
PMCPMC11186732
OpenAlexW4390109832

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.